Gene · 79679
NIH grants878
NIH grants whose papers are about the gene, through NIH's grant-paper links.
241 to 260 of 878
Download this page as JSON| Grant | Title | VTCN1 papers | Newest fiscal year |
|---|---|---|---|
| R01CA236226 | Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment | 1 | 2023 |
| R01CA240434 | Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma | 1 | 2023 |
| R01ES014639 | Mechanisms of Vascular Toxicity from Inhaled Toxicants | 1 | 2023 |
| R01GM112722 | Investigating regulators controlling differentiation potential of ES cells | 1 | 2023 |
| R01GM145940 | Mitochondria-Targeted Hydropersulfide Donors to Treat Anthracycline-Induced Cardiotoxicity | 1 | 2023 |
| R01HG011356 | Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations | 1 | 2023 |
| R01HL147187 | Mechanisms of ERG in Endothelial Activation | 1 | 2023 |
| R01HL151195 | Role of macrophage polarization in multi-organ fibrosis of chronic GVHD | 1 | 2023 |
| R01NS109742 | Deciphering MDSC function for GBM targeting | 1 | 2023 |
| R01NS111102 | Innovative systemic gene therapy for treating Parkinson's disease | 1 | 2023 |
| R03CA280302 | Tumor downstaging with small molecule therapeutics to enhance Uveal Melanoma metastasis eradication by B7-H3 CAR T cells | 1 | 2023 |
| R21AI169851 | Transcription factor A mitochondria in SLE pathogenesis | 1 | 2023 |
| R21CA258618 | The Roles of a Novel Immune-Checkpoint Receptor Complex in Driving T Cell Dysfunction in Cancer | 1 | 2023 |
| R25GM058268 | RISE: Educating Tomorrow's Biomedical Workforce | 1 | 2023 |
| R41AG078111 | A Therapeutic Role for Apolipoprotein-E in the Germ Theory of Alzheimer's Dementia | 1 | 2023 |
| R50CA243783 | Research Specialist in Cancer Systems Biology | 1 | 2023 |
| SC1GM136521 | Evaluation of HSPD1 (Heat Shock Protein, 60) as a theranostic target for breast cancer | 1 | 2023 |
| T32GM007739 | Weill Cornell/Rockefeller/Sloan Kettering MST Program | 1 | 2023 |
| U01CA224012 | Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens | 1 | 2023 |
| U01CA231978 | Systems analysis of aggressive prostate cancer pathology | 1 | 2023 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/79679/grants?page=13